CLDN1 upregulation after exposure to conventional chemotherapies used in colon cancer is, at least in part, functionally related to activation of the MAPKp38/GSK3β/Wnt/β-catenin pathway. The gene discussed is GSK3B; the disease is malignant colon neoplasm.